The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 1.83 — grey zone — between safe and distressedWatch
- Earnings-manipulation signal · Beneish M -2.65 — no flag raisedOK
- Earnings quality 100/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as Organon & Co. reports it. History and quarterly detail are in the app.
- Nexplanon/Implanon NXT$921.0M
- Zetia$342.0M
- Other$338.0M
- Atozet$324.0M
- Other Non-Opiod Pain, Bone and Dermatology$301.0M
Leadership changes
From Organon & Co.'s own filings, the day they're filed.
- Grace Puma · member · departureeff. 2025-11-03
- Joseph Morrissey · Chief Executive Officer · appointmenteff. 2025-10-27
- Kevin Ali · Chief Executive Officer · departureeff. 2025-10-26
Latest filings
- 10-Q · Quarterly report2026-07-31
- 8-K · Company announcement2026-07-31
- 8-K · Company announcement2026-07-23
- 8-K · Company announcement2026-07-17
- 8-K · Company announcement2026-06-11
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Organon & Co., every answer cited to the official filings🔒
- The Intelligence Brief — added when Organon & Co.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.